March 10th, 2013

Really Rapid Review — CROI 2013, Atlanta

As noted previously by Carlos del Rio in his nice summary, the Conference on Retroviruses and Opportunistic Infections (CROI) turned 20 this year. It also made it’s first-ever stop in Atlanta, home of many things that begin with “C” — CDC (note that insiders rarely say, “the CDC”), CNN, Coca Cola, and Carlos himself.

I’ll spare you the boring saga of just how messed up the travel was back to the Northeast as the conference came to a close — ugh — and jump right in on this Really Rapid Review™, loosely organized by prevention, treatment, and complications.

Apologies if I’ve left out your favorite, would love to hear what I missed — and I reserve the right to add a few based on your suggestions.  As for the conference venue, the meeting rooms were comfortable, audiovisuals reliable, the posters easy to see, and there were plenty of Coca Cola products available during the breaks.

Last but not least, I don’t think anyone announced where or when CROI 2014 will take place. Let the speculation begin!

8 Responses to “Really Rapid Review — CROI 2013, Atlanta”

  1. Ken Logue says:

    I have been tremendously impressed with the speed and thoroughness of your triple R’s (really rapid reviews), and this iteration lived up to expectations!

    Not necessarily one of my favorite presentations, but noteworthy, and perhaps of future significance, was the poster from the D:A:D group showing increased risk of non-AIDS defining cancers with cumulative ART and specifically with PI use (in the context of the well defined and described decreased risk of AIDS defining cancers with ART use). It including a graph showing cumulative risk increase by years on PI’s similar to the familiar CVS risk increase on PI’s that they previously presented.

    We will all recall the Abacavir controversy starting as a CROI poster from this same group.
    I walked away from the poster with questions such as “what do we really know about the safety of potent and long-term p450 inhibition”.
    I would be interested in your take on the poster.

    • Paul Sax says:

      Ken, thanks for pointing out that poster. It’s an interesting association, one that potentially could be explored in a meta-analysis of all the modern prospective clinical trials. Work on such a project is planned!


  2. Jose A Giron MD says:

    Very succint review.

    Glad to see the data supporting earlier HIV treatment and its likely effect in reducing a potential sanctuary population. Would like to read more on this topic as eliminating the sanctuary is the Holy Grail of HIV therapy. Early HIV therapy is like putting out the fire on the fence before it reaches the living room of the house.

    On the Hepatitis C front, do agree an all oral regimen seems very likely soon. We still need to have a comparison of regimens (all oral) to assess best efficacy, best length of therapy and best tolerability. But that will be similar to what has been done already in the HIV arena.

    It will be interesting to assess population data on Hepatitis C once the easier regimens become available . Given the possibility of eradication of the virus in a carrier, one would expect incidence will drop and secondary complications of Hepatitis C will also drop. An analysis of the economic impact of such phenomena will be interesting.

    Thank you , Paul , for your usual excellent review.

  3. JL says:

    I think this is worth mention in a recap though I’m sorry this was only a poster. One of the panelists from UNC discussed this during the disparities panel in the afternoon on Monday.

    Senior author Wafaa El-Sadr

    Highlights that HIV risk for black women differs substantially among sub-groups

  4. Phil Bolduc says:

    Hi Paul –
    I hope you’re not planning on retiring any time soon 🙂 For those of us who didn’t make it to CROI your reviews are super helpful – keep ’em coming!
    – Phil

  5. Omar Sued says:

    Hi Paul. Congratulations by the excellent review. The results from Reflate Study, comparing RAL 400 BID vs 800 BID when used with Rifampin are worthy to mention. Best

  6. Alexandre Barbosa says:

    Hey Paul,

    Congratulations for the great overview. Have you received any information about where the CROI 2014 will take place?


    • Paul Sax says:

      >>>any information about where the CROI 2014 will take place?

      Alexandre, not yet. Have asked around, no one seems to know where or when!

HIV Information: Author Paul Sax, M.D.

Paul E. Sax, MD

Contributing Editor

NEJM Journal Watch
Infectious Diseases

Biography | Disclosures | Summaries

Learn more about HIV and ID Observations.